Drawn from the work of world-renowned pharmacochemistry scientists, this book explores research that defines the emergence of rational drug design. Offering insight from their own specialized subjects, these pioneers highlight the variety of approaches being employed in this field, including those that start by considering either molecular mechanisms of drug action, or the metabolizing enzyme action occurring in the structure of a drug molecule. Another approach they explore is one that starts from the pathobiochemistry and pathophysiology of target diseases. Furthermore, the book also…mehr
Drawn from the work of world-renowned pharmacochemistry scientists, this book explores research that defines the emergence of rational drug design. Offering insight from their own specialized subjects, these pioneers highlight the variety of approaches being employed in this field, including those that start by considering either molecular mechanisms of drug action, or the metabolizing enzyme action occurring in the structure of a drug molecule. Another approach they explore is one that starts from the pathobiochemistry and pathophysiology of target diseases. Furthermore, the book also considers drug development that makes use of already developed compounds stored in data banks.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Introduction: Rational Drug DesignBased Mainly on the Pathobiochemistry of the Disease. Chemical, Biochemical, and Biological Aspects of Pathophysiological Conditions Inflammatory Mechanisms in Alzheimer's Disease and OtherNeurodegenerative Disorders.Treatment Development Strategies for Alzheimer's Disease.Lipoprotein-Associated Phospholipase A2 as a New PrognosticFactor for Coronary Artery Disease. New Molecular Targets for the Prevention and Treatment of Gastrointestinal Ulcers and Inflammation Stress Activates Corticotropin Releasing: Factor SignalingPathways: Implication in Functional Bowel Disorders. Classical Medicinal Chemistry Design, Synthesis, and Pharmacological Evaluation of High-Affinity and Selectivity Sigma-1 and Sigma-2 Receptor Ligands. Synthesis of Biologically Active Taxoids. From the Molecular Pharmacology to the Medicinal Chemistry of Cannabinoids. An Appraisal of Fomocaines: Current Situation and Outlook. Ligands for the GABA Recognition Site at the GABAA Receptor: Structure-Activity Studies. Strategies for Development of New Lead Structures for Inhibition of Acetylcholinesterase.Drug Design, Chemical and Molecular Aspects of Drug ActionDiscovery of Potent and Selective Inhibitors of HumanAldosterone Synthase (CYP11B2): A New Target for theTreatment of Congestive Heart Failure and MyocardialFibrosis-a Review. Thiocarboxanilides: A New Class of Nonnucleoside ReverseTranscriptase Inhibitors (NNRTIs) with Great Potential for theTreatment of Human Immunodeficiency Virus Type 1 (HIV-l)Infections.Histamine H3-Receptor Agonists and Antagonists: Chemical,Pharmacological, and Clinical Aspects.Anti-Inflammatory Actions of Flavonoids and StructuralRequirements for New Design.Molecular Mechanisms of H2O2-Induced DNA Damage: The Action of Desferrioxamine.LNA (Locked Nucleic Acid) and Functionalized LNA: Toward Efficient Gene Targeting.Drug - Xenobiotic Metabolism The Effect of Diet on Drug Metabolism.
Introduction: Rational Drug DesignBased Mainly on the Pathobiochemistry of the Disease. Chemical, Biochemical, and Biological Aspects of Pathophysiological Conditions Inflammatory Mechanisms in Alzheimer's Disease and OtherNeurodegenerative Disorders.Treatment Development Strategies for Alzheimer's Disease.Lipoprotein-Associated Phospholipase A2 as a New PrognosticFactor for Coronary Artery Disease. New Molecular Targets for the Prevention and Treatment of Gastrointestinal Ulcers and Inflammation Stress Activates Corticotropin Releasing: Factor SignalingPathways: Implication in Functional Bowel Disorders. Classical Medicinal Chemistry Design, Synthesis, and Pharmacological Evaluation of High-Affinity and Selectivity Sigma-1 and Sigma-2 Receptor Ligands. Synthesis of Biologically Active Taxoids. From the Molecular Pharmacology to the Medicinal Chemistry of Cannabinoids. An Appraisal of Fomocaines: Current Situation and Outlook. Ligands for the GABA Recognition Site at the GABAA Receptor: Structure-Activity Studies. Strategies for Development of New Lead Structures for Inhibition of Acetylcholinesterase.Drug Design, Chemical and Molecular Aspects of Drug ActionDiscovery of Potent and Selective Inhibitors of HumanAldosterone Synthase (CYP11B2): A New Target for theTreatment of Congestive Heart Failure and MyocardialFibrosis-a Review. Thiocarboxanilides: A New Class of Nonnucleoside ReverseTranscriptase Inhibitors (NNRTIs) with Great Potential for theTreatment of Human Immunodeficiency Virus Type 1 (HIV-l)Infections.Histamine H3-Receptor Agonists and Antagonists: Chemical,Pharmacological, and Clinical Aspects.Anti-Inflammatory Actions of Flavonoids and StructuralRequirements for New Design.Molecular Mechanisms of H2O2-Induced DNA Damage: The Action of Desferrioxamine.LNA (Locked Nucleic Acid) and Functionalized LNA: Toward Efficient Gene Targeting.Drug - Xenobiotic Metabolism The Effect of Diet on Drug Metabolism.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
